Regulus Therapeutics, Inc.
10614 Science Center Drive
San Diego
California
92121
United States
Tel: 858-202-6300
Fax: 858-202-6363
Website: http://www.regulusrx.com/
Email: careers@regulusrx.com
About Regulus Therapeutics, Inc.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.
Regulus is located in La Jolla, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.
Regulus Seeks Highly Motivated, Innovative and Passionate Team Members
338 articles about Regulus Therapeutics, Inc.
-
Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
8/13/2020
Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD") FDA Orphan Designation of RGLS4326 for ADPKD Appointment of Denis Drygin, Ph.D., as Chief Scientific Officer [13-August-2020] LA JOLLA, Calif. , Aug. 13, 2020 /PRNewsw
-
Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
8/6/2020
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 2:20 PM EDT.
-
Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
8/3/2020
Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis Drygin , Ph.D., as Chief Scientific Officer effective August 3 , 2020.
-
Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
7/29/2020
Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation to RGLS4326 for the treatment of patients
-
Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
7/22/2020
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of dosing for the Phase 1 multiple ascending dose ("MAD") clinical study for RGLS4326 in healthy volunteers.
-
Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
5/14/2020
Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
-
Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
3/12/2020
Regulus Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2019 and provided a corporate update.
-
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
2/13/2020
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced that it initiated dosing of the second cohort of its Phase 1 multiple ascending dose clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease.
-
Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326
12/16/2019
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration ("FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) (the "MAD study").
-
Regulus Therapeutics to Present at the Stifel Healthcare Conference
11/18/2019
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Stifel Healthcare Conference in New York City on Wednesday, November 20, 2019.
-
Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates
11/12/2019
Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326
-
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
10/16/2019
The poster presentation is available for download at http://regulusrx.com/publications.
-
Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
9/12/2019
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled, "Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease."
-
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
9/3/2019
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the H.C. Wainwright 21st Annual Global Investment Conference in New York City on Monday, September 9, 2019.
-
Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
8/29/2019
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2019.
-
Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
8/8/2019
Closing of First Tranche of $41.8 Million Private Placement of Equity
-
Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
7/30/2019
Regulus Therapeutics Inc. announced the appointment of Cris Calsada as its new Chief Financial Officer effective August 30, 2019.
-
Regulus Therapeutics Announces RGLS4326 Program Update
7/23/2019
Regulus Therapeutics Inc. announced a program update for RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
-
Regulus Announces New Additions to Board of Directors
6/11/2019
Regulus Therapeutics Inc. announced Jake Nunn and Simos Simeonidis, Ph.D. have been appointed to the Company's board of directors.
-
Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
5/9/2019
Regulus Therapeutics Inc. reported financial results for the first quarter ended March 31, 2019 and provided a summary of recent events.